PDE6D and exocrine pancreatic carcinoma: Deltarasin, the first reported PDEδ inhibitor, attenuated RAS oncogenic signalling by occupying the prenyl binding pocket of PDEδ and inhibited the proliferation of human pancreatic carcinoma cells both in vitro and in vivo.21